TRUDHESA

Clinical safety rating: caution

Comprehensive clinical and safety monograph for TRUDHESA (TRUDHESA).

How it works

TRUDHESA is a fixed-dose combination of sumatriptan (a serotonin 5-HT1B/1D receptor agonist) and naproxen sodium (a nonsteroidal anti-inflammatory drug). Sumatriptan causes vasoconstriction of intracranial blood vessels and inhibits the release of pro-inflammatory neuropeptides, while naproxen inhibits cyclooxygenase enzymes (COX-1 and COX-2), reducing prostaglandin synthesis.

What the body does with it

Metabolism	Sumatriptan is metabolized primarily by monoamine oxidase A (MAO-A). Naproxen is metabolized by CYP2C9 (major) and CYP1A2 (minor).
Excretion	Trudhesa (dihydroergotamine mesylate) is primarily eliminated via hepatic metabolism, with approximately 10% excreted unchanged in urine and 90% as metabolites in bile/feces.
Half-life	Terminal elimination half-life is approximately 2.4 hours (range 1.7-3.6 hours) following intravenous administration. Clinical context: Due to rapid clearance, repeated dosing is recommended for acute migraine attacks.
Protein binding	Approximately 90-93% bound to plasma proteins, primarily to albumin.
Volume of Distribution	Volume of distribution (Vd) is approximately 14 L/kg (range 10-20 L/kg), indicating extensive tissue distribution, including binding to serotonin receptors in the CNS.
Bioavailability	Intranasal administration: Absolute bioavailability approximately 15-20% (range 10-30%), due to extensive first-pass hepatic metabolism.
Onset of Action	Intranasal administration: Onset of relief within 30 minutes; peak effect at 1-2 hours.
Duration of Action	Duration of therapeutic effect typically lasts 4-6 hours. Clinical note: Some patients may require a second dose if symptoms recur within 24 hours, with a maximum of 3 mg/day.

Classification & Brands

Dosing & administration

10 mg intranasally once, may repeat after 2 hours if needed; maximum 20 mg per 24 hours.

Dosage form	SPRAY, METERED
Renal impairment	No dosage adjustment required for mild to moderate renal impairment; no data for severe impairment (eGFR <30 mL/min/1.73 m2).
Liver impairment	Contraindicated in severe hepatic impairment (Child-Pugh class C); use with caution in moderate impairment (Child-Pugh class B) with no specific dose adjustment defined.
Pediatric use	Not approved for use in pediatric patients; safety and efficacy not established.
Geriatric use	No specific dose adjustment recommended, but consider potential increased sensitivity to adverse effects due to comorbidities or concomitant medications.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for TRUDHESA (TRUDHESA).

Breastfeeding	Topiramate is excreted into breast milk; M/P ratio 0.86. Infant exposure estimated at 10-20% of maternal weight-adjusted dose. Monitor for diarrhea, drowsiness, and poor feeding.
Teratogenic Risk	Trimester 1: Increased risk of congenital abnormalities, particularly neural tube defects, due to topiramate exposure. Trimester 3: Risk of transient neonatal hyperbilirubinemia and sulfonamide-related adverse effects.
Fetal Monitoring

Warnings & precautions

■ FDA Black Box Warning

Cardiovascular Risk: NSAIDs, including naproxen, increase the risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular risk factors or existing cardiovascular disease are at greater risk.

Side Effect Profile

Serious Effects

Absolute Contraindications

History of ischemic heart disease, coronary artery disease, or cerebrovascular disease; peripheral vascular disease; uncontrolled hypertension; hemiplegic or basilar migraine; recent use (within 24 hours) of another 5-HT1 agonist or ergotamine; concurrent MAO-A inhibitor use; history of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs; severe hepatic impairment; third trimester of pregnancy.

Clinical Precautions

Precautions

Cardiovascular and cerebrovascular effects; risk of myocardial infarction, stroke, and hypertension; gastrointestinal bleeding (NSAID-related); serotonin syndrome with concomitant serotonergic drugs; renal effects; anaphylactic reactions; exacerbation of asthma; sulfonamide allergy (cross-reactivity).

Clinical Tips & Counseling

Drug interactions

Loading safety data…

TRUDHESA

Clinical safety rating: caution

Comprehensive clinical and safety monograph for TRUDHESA (TRUDHESA).

How it works

What the body does with it

Metabolism	Sumatriptan is metabolized primarily by monoamine oxidase A (MAO-A). Naproxen is metabolized by CYP2C9 (major) and CYP1A2 (minor).
Excretion	Trudhesa (dihydroergotamine mesylate) is primarily eliminated via hepatic metabolism, with approximately 10% excreted unchanged in urine and 90% as metabolites in bile/feces.
Half-life	Terminal elimination half-life is approximately 2.4 hours (range 1.7-3.6 hours) following intravenous administration. Clinical context: Due to rapid clearance, repeated dosing is recommended for acute migraine attacks.
Protein binding	Approximately 90-93% bound to plasma proteins, primarily to albumin.
Volume of Distribution	Volume of distribution (Vd) is approximately 14 L/kg (range 10-20 L/kg), indicating extensive tissue distribution, including binding to serotonin receptors in the CNS.
Bioavailability	Intranasal administration: Absolute bioavailability approximately 15-20% (range 10-30%), due to extensive first-pass hepatic metabolism.
Onset of Action	Intranasal administration: Onset of relief within 30 minutes; peak effect at 1-2 hours.
Duration of Action	Duration of therapeutic effect typically lasts 4-6 hours. Clinical note: Some patients may require a second dose if symptoms recur within 24 hours, with a maximum of 3 mg/day.

Classification & Brands

Dosing & administration

10 mg intranasally once, may repeat after 2 hours if needed; maximum 20 mg per 24 hours.

Dosage form	SPRAY, METERED
Renal impairment	No dosage adjustment required for mild to moderate renal impairment; no data for severe impairment (eGFR <30 mL/min/1.73 m2).
Liver impairment	Contraindicated in severe hepatic impairment (Child-Pugh class C); use with caution in moderate impairment (Child-Pugh class B) with no specific dose adjustment defined.
Pediatric use	Not approved for use in pediatric patients; safety and efficacy not established.
Geriatric use	No specific dose adjustment recommended, but consider potential increased sensitivity to adverse effects due to comorbidities or concomitant medications.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for TRUDHESA (TRUDHESA).

Breastfeeding	Topiramate is excreted into breast milk; M/P ratio 0.86. Infant exposure estimated at 10-20% of maternal weight-adjusted dose. Monitor for diarrhea, drowsiness, and poor feeding.
Teratogenic Risk	Trimester 1: Increased risk of congenital abnormalities, particularly neural tube defects, due to topiramate exposure. Trimester 3: Risk of transient neonatal hyperbilirubinemia and sulfonamide-related adverse effects.
Fetal Monitoring